Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context.
MYSTIC
PACIFIC
durvalumab
non-small cell lung cancer
rechallenge
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
04
2020
accepted:
25
06
2020
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
9
8
2020
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a programmed death ligand 1 inhibitor) is the unique drug approved as consolidation treatment after chemo-radiotherapy. This article reviews the pharmacological properties, clinical activity and safety of durvalumab as monotherapy or in combination with chemotherapy or other ICIs in the therapeutic strategy of NSCLC patients.
Identifiants
pubmed: 32764980
doi: 10.2147/OTT.S259308
pii: 259308
pmc: PMC7369644
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
6885-6896Informations de copyright
© 2020 Gullapalli et al.
Déclaration de conflit d'intérêts
SG reports no conflicts of intertest related to the current work or outside this one. JR reports no conflicts of interest related to the current work; is a member of advisory board in Boehringer, BMS, and OSE-Immunotherapeutics; and speaker for Pfizer; received travel fees from OSE-immunotherapeutics, BMS, AstraZeneca, and Roche outside the current work. LH reports no conflicts of interest related to the current work; received research funding from Roche, Boehringer Ingelheim, AstraZeneca (all institution); and is a member of advisory board in Boehringer, BMS, Lilly, Roche, Pfizer, Takeda, MSD, Boehringer Ingelheim (all institution); speaker for MSD; received travel/conference reimbursement from Roche, BMS (self); grants for mentorship program with key opinion leaders funded by AstraZeneca; fees for educational webinars from Quadia (self), and fees for interview sessions funded by Roche (institution) outside of current work. GL reports no conflicts of interest related to the current work; received institutions grants from Merck, Roche Genentech, AstraZeneca, BMS, EMD Serono, Novartis, Tesaro, Blueprint medicines, G1 Therapeutics US NIH/NCI, Singapore A-Star, Brazil CNPq outside the current work. The authors report no other conflicts of interest in this work.
Références
J Clin Oncol. 2020 Jan 20;38(3):271-280
pubmed: 31751163
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Ann Oncol. 2020 Mar 21;:
pubmed: 32209338
Lung Cancer. 2020 Feb;140:99-106
pubmed: 31911324
Lancet Oncol. 2019 Jul;20(7):924-937
pubmed: 31122901
Br J Cancer. 2006 Apr 24;94(8):1099-106
pubmed: 16622435
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Lung Cancer. 2020 May;143:1-11
pubmed: 32169783
J Thorac Oncol. 2020 Feb;15(2):248-257
pubmed: 31778797
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Cancer Discov. 2016 Dec;6(12):1382-1399
pubmed: 27663893
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
J Clin Oncol. 2020 May 10;38(14):1580-1590
pubmed: 32078391
Ann Oncol. 2019 Aug 1;30(8):1321-1328
pubmed: 31125062
N Engl J Med. 2018 May 24;378(21):1976-1986
pubmed: 29658848
J Thorac Oncol. 2019 May;14(5):933-939
pubmed: 30763730
J Thorac Oncol. 2020 Feb;15(2):288-293
pubmed: 31622733
JAMA Oncol. 2019 Mar 1;5(3):358-365
pubmed: 30543349
Ann Oncol. 2020 May;31(5):609-618
pubmed: 32201234
Ann Oncol. 2020 Apr;31(4):501-506
pubmed: 32107097
Ann Oncol. 2018 Oct 1;29(10):2085-2091
pubmed: 30165371
Clin Lung Cancer. 2017 May;18(3):333-339
pubmed: 27923550
J Clin Oncol. 2018 Aug 10;36(23):2366-2377
pubmed: 29787357
J Thorac Oncol. 2019 Oct;14(10):1794-1806
pubmed: 31228626
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Lancet Oncol. 2018 Apr;19(4):521-536
pubmed: 29545095
JAMA Oncol. 2019 Jun 1;5(6):847-855
pubmed: 30869743
Expert Rev Anticancer Ther. 2019 Dec;19(12):1009-1016
pubmed: 31782989
Lancet Oncol. 2014 Jan;15(1):e42-50
pubmed: 24384493
Ann Oncol. 2019 Feb 1;30(2):161-165
pubmed: 30624547
Clin Cancer Res. 2020 May 15;26(10):2354-2361
pubmed: 32102950
JCO Precis Oncol. 2019;3:
pubmed: 31192313
Ann Oncol. 2020 Apr;31(4):507-516
pubmed: 32139298
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
Lancet Oncol. 2017 Dec;18(12):1600-1609
pubmed: 29129441
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
Lancet Oncol. 2016 Mar;17(3):299-308
pubmed: 26858122
Nat Med. 2018 Sep;24(9):1441-1448
pubmed: 30082870
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Ann Oncol. 2019 Oct 1;30(10):1653-1659
pubmed: 31435660
J Thorac Oncol. 2018 Aug;13(8):1156-1170
pubmed: 29777823
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
J Clin Oncol. 2020 May 10;38(14):1505-1517
pubmed: 32150489
Cancer Immunol Res. 2015 Sep;3(9):1052-62
pubmed: 25943534
JAMA Oncol. 2019 Jul 25;:
pubmed: 31343665
Lancet Oncol. 2019 Dec;20(12):1670-1680
pubmed: 31601496
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
J Thorac Oncol. 2020 May;15(5):816-826
pubmed: 32036071
J Thorac Oncol. 2018 Aug;13(8):1128-1137
pubmed: 29723688
J Clin Oncol. 2019 Oct 1;37(28):2518-2527
pubmed: 31154919
Lancet Oncol. 2020 Mar;21(3):387-397
pubmed: 32035514
J Thorac Oncol. 2018 Dec;13(12):1884-1896
pubmed: 30267840
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
J Clin Oncol. 2018 Jun 10;36(17):1675-1684
pubmed: 29570421
Lung Cancer. 2019 Jul;133:83-87
pubmed: 31200833